First Round of Hospital Beta-Testing for AsepticSure is Completed

Medizone International Inc. announces successful completion of the first phase of AsepticSure beta testing at Hotel Dieu Hospital, an ambulatory care teaching and research hospital affiliated with Queen's University in Kingston, Ontario, Canada.

"We are absolutely delighted with the results, says Dr. Michael E. Shannon. Pre-inoculated stainless steel test discs as well as carpet swatches typically found in many healthcare facilities were placed in selected locations to assess for antimicrobial effects. Not only were 100 percent of the MRSA and C. difficile spores eliminated from the stainless steel discs (7.1 logs bacterial kill for MRSA and 6.2 log bacterial kill for C difficile spores), the pathogens were also completely eliminated from all contaminated carpet samples, something unachievable with any other technology we are aware of. Thus, the system performed to our highest expectations. The AsepticSure system has proven to be able to achieve a very high level of microbial kill to the sterilization standard of > 6 log (99.9999 percent) in the laboratory setting and now in a hospital setting."

Dr. David Pichora, a leading orthopedic and hand surgeon, and the hospital's CEO, notes, "I am pleased that Hotel Dieu Hospital has been able to participate in what appears to be a promising breakthrough in addressing the global challenge of reducing hospital acquired infections. The results of the AsepticSure sterilization technology tests are encouraging. Technology that could help hospitals improve patient safety, reduce infection rates and reduce costs is exciting, indeed. We are pleased to be participating in this safety initiative and we look forward to continued participation."

Medizone International, Inc. is a research and development company engaged in developing its AsepticSure System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, patient rooms, schools and other critical infrastructure. A government variant is being developed for bio-terrorism counter measures with additional variants for sports facilities and food processing applications.